Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients

Cathelijne van der Feen, Hubert P. J. van der Doef, Cornelis K. van der Ent, Roderick H. J. Houwen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)


Background: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking.

Methods: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid.

Results: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59) kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4) kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55) kPa/year (P = 0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51) kPa/year.

Conclusion: UDCA reduced liver stiffness in patients with well-defined, mild liver disease. (C) 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)834-838
Number of pages5
JournalJournal of Cystic Fibrosis
Issue number6
Publication statusPublished - Nov-2016


  • Cystic fibrosis liver disease
  • Ursodeoxycholic acid
  • Liver stiffness measurement
  • Fibroscan

Cite this